IQOS Supplier IntreTech Saw Decline in E-Cigarette Revenue by 2023

Business by 2FIRSTS.ai
Apr.29.2024
IQOS Supplier IntreTech Saw Decline in E-Cigarette Revenue by 2023
IntreTech reveals e-cigarette revenue drop in 2023 due to shift to fourth-generation products, receives buy rating from Huaxin Securities.

On April 28, IntreTech, a company listed on the Shenzhen Stock Exchange (stock code: 002925), revealed during an institutional research interview that its e-cigarette business revenue is expected to decrease in 2023.

 

IntreTech stated that the main reason for the decrease in revenue from supplying plastic components for third-generation e-cigarette products is due to the transition towards fourth-generation products as customers' development strategies change. The company's core components and complete devices are primarily supplying customers' fourth-generation products, which have successfully entered mass production and further established a business system of "components + parts + complete devices".

 

On the same day, Huaxin Securities conducted research on IntreTech and released a research report titled "Short-term Performance Pressure, Waiting for Volume Increase in the e-cigarette Business". The report gave IntreTech a buy rating.

 

According to reports, IntreTech, a supplier of precision plastic components for Philip Morris International's (PMI) e-cigarette device IQOS, mainly caters to the e-cigarette business. Previously, a comprehensive report on the HNB industry chain issued by China Merchants Securities pointed out that IntreTech's e-cigarette component business is closely linked with Philip Morris International (PMI). With the continuous expansion of the HNB industry and the consolidation of the company's competitive advantages, it is expected that the innovative consumer electronics business will lead the company's overall performance into a new stage.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Philippine FDA Requires Licenses for Vape Products with Medical Claims
Philippine FDA Requires Licenses for Vape Products with Medical Claims
The Philippine Food and Drug Administration has announced that establishments selling vaporized nicotine and non-nicotine products and novel tobacco products with medicinal or therapeutic claims must secure Licenses to Operate. Such products are also required to be registered as pharmaceutical products through the Center for Drug Regulation and Research. The FDA urged stakeholders to comply with the new requirements to ensure product safety, efficacy and quality.
Dec.22 by 2FIRSTS.ai
Morocco Lawmakers Propose Excise Taxes on Vapes, Hookah, and Nicotine Alternatives
Morocco Lawmakers Propose Excise Taxes on Vapes, Hookah, and Nicotine Alternatives
Members of the Socialist Union of Popular Forces (USFP) have submitted amendments to Article 7 of the Finance Bill, introducing new excise taxes on e-cigarette liquids, hookah accessories, and non-tobacco nicotine products. The proposal also revises VAT exemptions and insurance tax rates to enhance fiscal fairness and revenue clarity.
Nov.11 by 2FIRSTS.ai
Russian State Duma Passes Ban on Tobacco and Vape Sales at Public Transport Stops
Russian State Duma Passes Ban on Tobacco and Vape Sales at Public Transport Stops
Russia’s State Duma has approved, in its third reading, a law banning the sale of cigarettes and electronic cigarettes at public transport stops. The measure expands existing restrictions on tobacco sales at transport infrastructure facilities and aims to reduce accessibility, particularly among young people. The law includes an exemption for small settlements where such kiosks are the only sales points and will take effect on September 1, 2026.
Dec.18 by 2FIRSTS.ai
Illegal Disposable Vapes Still Sold in Nottingham Six Months After UK Ban: LBC Investigation
Illegal Disposable Vapes Still Sold in Nottingham Six Months After UK Ban: LBC Investigation
According to LBC, a follow-up investigation in Nottingham found that four out of 14 shops visited still sold illegal disposable vapes, six months after the UK Government’s ban took effect. Although fewer retailers appeared to be offering banned products compared with an earlier visit, illegal vapes remain available despite ongoing enforcement efforts.
Dec.03 by 2FIRSTS.ai
U.S. FDA Unveils Next-Generation Agentic AI Tool to Boost Review and Regulatory Efficiency
U.S. FDA Unveils Next-Generation Agentic AI Tool to Boost Review and Regulatory Efficiency
The U.S. FDA has announced the agency-wide deployment of new agentic AI capabilities, providing all employees with an optional multi-step task automation tool. Building on the broad adoption of its earlier large-language-model system, Elsa, the FDA aims to use this next-generation AI workflow to accelerate product review, regulatory oversight, and internal operations, while maintaining strict human supervision and data security.
Dec.02 by 2FIRSTS.ai
Tobacco-Free Kids Condemns PMI for Marketing Zyn to Youth via F1 Sponsorship
Tobacco-Free Kids Condemns PMI for Marketing Zyn to Youth via F1 Sponsorship
Yolonda C. Richardson, President and CEO of the Campaign for Tobacco-Free Kids, issued a statement on December 10, 2025, condemning Philip Morris International (PMI) for partnering with Ferrari to promote Zyn nicotine pouches on Formula 1 cars. She said PMI’s claim that the sponsorship targets adults is misleading, as F1’s audience has become increasingly young—with over 4 million children aged 8–12 now following the sport.
Dec.12 by 2FIRSTS.ai